echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Net profit growth is expected to exceed 1000%! The potential behind the "new expensive" of pharmaceutical stocks

    Net profit growth is expected to exceed 1000%! The potential behind the "new expensive" of pharmaceutical stocks

    • Last Update: 2021-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 19th, the first pharmaceutical stock after the rat was listed on the Science and Technology Board: Jiang Bio's first day traded at 90 yuan, up about 108% from the issue price of 43.22 yuan, and the intraday high of 92.88 yuan.
    close, the stock was up 73.25 per cent at 74.8 yuan.
    in the field of molecular diagnostics once again put biomedicine in the spotlight.
    Recently listed companies have been disclosed announcements, mixed, although the performance of pre-decrease, continued losses, first loss and other performance worries of the company total about 30% of the total, but pharmaceutical stocks still have eye-catching performance areas.
    pharmaceutical stocks, more than 180 companies expect net profit to grow by more than 100% in 2020 compared with the previous year, and some expect to grow by more than 1000%.
    a rare "V" reversal, as the National Bureau of Statistics reported today with a trillion-dollar GDP growth.
    "out-of-epidemic" growth carrying the banner of the global epidemic is still fighting the virus, the huge demand for testing also let the performance of related companies grow rapidly.
    net profit attributable to shareholders of listed companies is expected to be RMB200,000-220,000 in 2020, up 2069.63% to 2286.59% YoY, according to a recent announcement by Danan Gene.
    is quite surprising, both reasonable and unexpected.
    relying on Zhongshan University's scientific research platform, molecular diagnostic technology-led enterprises in public health, infectious diseases and other areas related to the rapid development of the situation, has made great dedication, but also achieved rapid development.
    In fact, according to the latest semi-annual report released by Daan Gene, its net profit attributable to shareholders of listed companies in the first half of 2020 was about 778 million yuan, up 1186.48 percent year-on-year, and operating income was about 2.133 billion yuan, up 313.63 percent year-on-year.
    companies stand out against the backdrop of the deep impact of the outbreak? Looking at the announcement of listed companies, Oriental Bio's 2020 full-year results forecast issued on the first day of New Year's Day is also a point of view: the annual net profit of attributable parents is expected to increase by about 1795.10% YoY, or 1.556 billion yuan, and net profit attributable to non-attributed parents will increase by about 1925.06 percent YoY, or 1.539 billion yuan.
    In addition, on the evening of January 14, Zhende Medical announced a pre-announcement of the 2020 annual results, which forecast a net profit attributable to shareholders of listed companies of RMB2,383 million to RMB2.461 billion compared with a year earlier.
    net profit growth is expected to be between 1517.83% and 1567.52%.
    It is clear that this is very different from the overall results of the pharmaceutical industry: according to the latest statistics of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, the global economy will decline in 2020 due to the new crown epidemic, although China's pharmaceutical economy in a series of steady growth measures, pharmaceutical manufacturing business income after two quarters of decline, the growth rate in August from negative to positive.
    From the performance of pharmaceutical listed companies, operating income in the first three quarters increased by 5.1%, profit growth of 26.7%, but in the overall recovery, some sub-sectors have not yet recovered from the epidemic, January-October chemical agent industry revenue fell 4.3% YoY, profits fell 9.3%, and nearly half of the relevant listed companies also lost net profit.
    And these outbursts of new highs, net profit growth rate of more than 1000%, are related to epidemic prevention products, such as in-body diagnostic reagents, in-body diagnostic equipment, such as the outbreak brought huge testing demand.
    Long-term cattle need to look at the fundamentals if the policy, capital flow and the new crown outbreak are only factors affecting the short-term fluctuations of the pharmaceutical industry, in the long run, medicine as a very vital track, support point in the final analysis or product line layout.
    First of all, from a policy point of view, based on adhering to the expansion of domestic demand this strategic basis, medical care is "the just need in domestic demand" will make the pharmaceutical sector become a highly valued industry, the enthusiasm of the industry will be ignited.
    2020 CDE to undertake a total of 10,312 new drug registration applications to accept the number.
    , 828 applications for registration of domestic 1 class of innovative drugs.
    , a single domestic overseas authorization amounting to $2.2 billion has been successfully held in hand.
    from the current pharmaceutical industry market value ranking TOP10, Hengrui Pharmaceuticals, Pharmaceuticals Mingkangde, Tablet , Yunnan White Medicine and Fosun Pharmaceuticals and other enterprises are in the product layout has a strong competitive advantage.
    Such as Hengrui Pharmaceuticals in the first three quarters of 2020 research and development investment has increased to 3,344 million yuan, accounting for about 23% of the total operating costs, only the first three quarters have issued a total of 39 clinical trial approval announcements.
    it can be judged that the domestic innovative pharmaceutical companies gradually accelerate the integration into the international new drug research environment, at the same time, the resulting series of innovative results will also become the main driving force for the development of the domestic pharmaceutical market, but also the capital pursuit of the incense.
    , the pharmaceutical industry is closely related to the human life cycle of the industry.
    According to the Blue Book of the Great Health Industry: China's Great Health Industry Development Report, the number of elderly people aged 60 and over in China will reach 483 million in 2050, and the total consumption of the elderly population will be 61.26 trillion yuan, 1.89 times and 8.73 times respectively in 2020.
    Chinese aging of the population and the aging of the elderly population are showing a gradual deepening trend.
    health needs brought about by the aging of the pharmaceutical industry is growing, which is an important industry foundation for the future of the pharmaceutical industry.
    is china's disease spectrum is showing an expanding trend.
    nearly three decades, the burden of communicable diseases and nutrition-related diseases has decreased significantly, the burden of non-communicable diseases has increased, and cancer, cardiovascular disease and diabetes have become mainstream diseases.
    meters of intranet data show that from the therapeutic field, sales of TOP3 categories are anti-tumor and immunomodulants, digestive and metabolic drugs and systemic anti-infective drugs.
    the short-term fatality rate of these diseases is low, but it has the characteristics of long-term, serious and high treatment costs, which is precisely the pharmaceutical industry long-term cattle important industry fundamentals.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.